Trial Profile
Delaying or preventing the complications of Type-1 diabetes by adding the selective mineralocorticoid receptor antagonist eplerenone to standard medication for patients with Type-1 Diabetes.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BART-1
- Sponsors Pfizer
- 07 Feb 2014 New trial record